Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
Volume
22
Pagination
1926 - 1937
DOI
10.1016/j.bbmt.2016.06.004
Journal
Biol Blood Marrow Transplant
Issue
Metadata
Show full item recordAbstract
Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved progression-free survival with autologous transplantation after combination chemotherapy induction. These trials were performed before novel agents were introduced; subsequently, combinations of immunomodulatory drugs and proteasome inhibitors as induction therapy have significantly improved rates and depth of response. Ongoing randomized trials are testing whether conventional autologous transplantation continues to improve responses after novel agent induction. Although these results are awaited, it is important to review strategies for improving outcomes after ASCT. Conditioning before ASCT with higher doses of melphalan and combinations of melphalan with other agents, including radiopharmaceuticals, has been explored. Tandem ASCT, consolidation, and maintenance therapy after ASCT have been investigated in phase III trials. Experimental cellular therapies using ex vivo-primed dendritic cells, ex vivo-expanded autologous lymphocytes, Killer Immunoglobulin Receptor (KIR)-mismatched allogeneic natural killer cells, and genetically modified T cells to augment ASCT are also in phase I trials. This review summarizes these strategies and highlights the importance of exploring strategies to augment ASCT, even in the era of novel agent induction.
Authors
Maybury, B; Cook, G; Pratt, G; Yong, K; Ramasamy, KURI
https://www.sciencedirect.com/science/article/pii/S1083879116301355?via%3Dihubhttp://qmro.qmul.ac.uk/xmlui/handle/123456789/47043
Collections
Language
Licence information
Copyright statements
Related items
Showing items related by title, author, creator and subject.
-
Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.
Uddin, S; Russell, P; Farrell, M; Davy, B; Taylor, J; Agrawal, SG (2015-04)OBJECTIVES: Biosimilar filgrastim was compared with lenograstim for autologous haematopoietic stem-cell transplant (HSCT) in patients with haematological malignancies. Data from a separate group of sibling donors who ... -
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators.
Pockley, AG; Lindsay, JO; Foulds, GA; Rutella, S; Gribben, JG; Alexander, T; Snowden, JA (2018)Patients with treatment refractory Crohn's disease (CD) suffer debilitating symptoms, poor quality of life, and reduced work productivity. Surgery to resect inflamed and fibrotic intestine may mandate creation of a stoma ... -
Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report
Passweg, JR; Baldomero, H; Bader, P; Bonini, C; Duarte, RF; Dufour, C; Gennery, A; Kroeger, N; Kuball, J; Lanza, F (2017-06)